Table 2. RRR describing clinical and pathological correlates of BRAF mutation estimated in univariate and multivariate multinomial regression analyses.

	BRAF mutant vs BRAF/NRAS wild-typea						BRAF mutant vs NRAS mutantb
	Univariate analysis			Multivariate analysis			Univariate analysis			Multivariate analysis
Clinicopathological variable	RRR	95% CI	P-value	RRR	95% CI	P-value	RRR	95% CI	P-value	RRR	95% CI	P-value
Patient sex
Male	1.00			1.00			1.00			1.00
Female	1.45	1.09–1.92	0.01	1.21	0.88–1.67	0.24	1.21	0.87–1.69	0.3	1.30	0.89–1.91	0.18
Patient age
<50 years	1.00			1.00			1.00			1.00
⩾50 years	0.40	0.30–0.55	<0.001	0.48	0.34–0.67	<0.001	0.28	0.18–0.42	<0.001	0.29	0.19–0.45	<0.001
Anatomical location
Head & neck	1.00			1.00			1.00			1.00
Trunk	2.39	1.65–3.47	<0.001	2.14	1.41–3.24	<0.001	0.92	0.54–1.55	0.8	0.77	0.43–1.36	0.4
Upper extremity	1.16	0.78–1.73	0.5	1.06	0.68–1.66	0.8	0.42	0.24–0.72	0.002	0.38	0.21–0.69	0.002
Lower extremity	2.11	1.37–3.26	0.001	1.66	1.02–2.71	0.04	0.56	0.32–0.98	0.04	0.41	0.22–0.77	0.005
Breslow thickness
<1.0 mm	1.00			1.00			1.00			1.00
1.00–2.0 mm	1.66	1.15–2.40	0.007	1.69	1.12–2.53	0.011	0.42	0.27–0.67	<0.001	0.36	0.22–0.59	<0.001
2.01–4.0 mm	1.02	0.71–1.47	0.9	1.23	0.80–1.88	0.3	0.39	0.24–0.62	<0.001	0.39	0.23–0.66	<0.001
>4.0 mm	1.03	0.68–1.56	0.9	1.39	0.83–2.35	0.22	0.59	0.34–1.05	0.07	0.58	0.31–1.13	0.11
Histologic subtype
SSM	1.00			1.00			1.00			1.00
NM	0.78	0.56–1.07	0.13	0.88	0.60–1.31	0.5	0.82	0.56–1.19	0.3	1.15	0.75–1.78	0.5
LMM	0.19	0.10–0.35	<0.001	0.33	0.17–0.65	0.001	1.01	0.36–2.87	1.0	1.18	0.40–3.49	0.8
Mitotic rate (n/mm2)
<5	1.00						1.00
5–9	1.15	0.79–1.67	0.5				0.73	0.48–1.10	0.13
⩾10	1.03	0.70–1.52	0.9				0.87	0.55–1.38	0.6
Ulceration
No	1.00						1.00
Yes	1.20	0.88–1.64	0.3				0.92	0.64–1.32	0.7

Abbreviations: CI=confidence interval; LMM=lentigo maligna melanoma; NM=nodular melanoma; RRR=relative risk ratio; SSM=superficial spreading melanoma.

^aBRAF/NRAS wild-type as the reference category.

^bNRAS mutant as the reference category.

Multivariate analysis adjusted for patient sex, patient age, anatomical location of the primary tumour, Breslow thickness and histologic subtype. Mitotic rate and ulceration were excluded as there were not found to be associated with mutation status in univariate analyses.